Securities Registration Statement (simplified Form) (s-3/a)
21 Junho 2021 - 7:17AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on June 21, 2021
Registration
No. 333-256790
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Amendment
No. 1
to
FORM
S-3
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Protagenic
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
149
Fifth Avenue
New York, New York 10010
212-994-8200
|
|
06-1390025
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Address,
including zip code, and
telephone number, including area
code, of registrant’s principal
executive offices)
|
|
(I.R.S.
Employer
Identification
Number)
|
Garo
Armen
Executive
Chairman
Protagenic
Therapeutics, Inc.
149 Fifth Avenue
New York, New York 10010
212-994-8200
(Name,
address, including zip code, and telephone number,
including area code, of agent for service)
With
copies to:
Dean
M. Colucci, Esq.
Michelle
Geller, Esq.
Kelly
R. Carr, Esq.
Duane
Morris LLP
1540
Broadway
New
York, NY 10036
Telephone:
(973) 424-2020
Approximate
date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.
If
the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box. [ ]
If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, as amended (“Securities Act”), other than securities offered only in connection with dividend or
interest reinvestment plans, check the following box. [ X ]
If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act Registration Statement number of the earlier effective Registration Statement
for the same offering. [ ]
If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act Registration Statement number of the earlier effective Registration Statement for the same offering. [ ]
If
this Form is a Registration Statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. [ ]
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. [ ]
Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”
and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check
one):
|
Large
accelerated filer
|
[ ]
|
|
Accelerated
filer
|
[ ]
|
|
Non-accelerated
filer
|
[ ]
|
|
Smaller
reporting company
|
[X]
|
|
|
|
|
Emerging
growth company
|
[ ]
|
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall
become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
This
Amendment No. 1 to Form S-3 (this “Amendment”) is being filed to amend the Registration Statement on Form S-3 (File
No. 333-256790) originally filed by Protagenic Therapeutics, Inc. on June 4, 2021. The sole purpose of this Amendment is to file
an amended version of the Exhibit Index in Item 16 of Part II. Accordingly, this Amendment consists only of the facing page, this
explanatory note, Item 16 of Part II and the exhibit list therein, and the signature pages.
Item
16. Exhibits.
Exhibit
Number
|
|
Description
of Document
|
|
1.1*
|
|
Form
of Underwriting Agreement.
|
|
3.1†
|
|
Third Amended and Restated Certificate of Incorporation of Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 20, 2016).
|
|
3.2†
|
|
Certificate of Designations, Powers, Preferences and Other Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof of Series B Convertible Preferred Stock of Atrinsic, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on February 5, 2016).
|
|
3.3†
|
|
Second Amended and Restated Bylaws of Protagenic Therapeutics, Inc., (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 1, 2018).
|
|
4.1*
|
|
Form
of warrant agreement and warrant certificate
|
|
4.2*
|
|
Form
of specimen preferred stock certificate
|
|
4.3*
|
|
Certificate
of designation for preferred stock
|
|
4.4†
|
|
Form
of Indenture with respect to senior debt securities, between the registrant and one or more trustees to be named.
|
|
4.5†
|
|
Form of Indenture with respect to subordinated debt securities, between the registrant and one or more trustees to be named.
|
|
4.6*
|
|
Form
of debt security
|
|
4.7*
|
|
Form
of rights agreement
|
|
5.1†
|
|
Opinion of Duane Morris LLP.
|
|
21.1†
|
|
Subsidiaries (Incorporated by reference to Exhibit 21.1 to Company’s Annual Report on Form 10-K, as filed with the SEC on March 24, 2021)
|
|
23.1†
|
|
Consent of MaloneBailey, LLP, Independent Registered Public Accounting Firm.
|
|
23.2†
|
|
Consent of Duane Morris LLP (included in Exhibit 5.1).
|
|
24.1†
|
|
Powers of Attorney
|
|
25.1**
|
|
Statement
of Eligibility of Trustee on Form T-1 of Trustee under the Senior Debt Indenture.
|
|
25.2
**
|
|
Statement
of Eligibility of Trustee on Form T-1 of Trustee under the Subordinated Debt Indenture.
|
*
To the extent applicable, to be filed by a post-effective amendment or as an exhibit to a document filed under the Exchange Act
and incorporated by reference herein.
**
To be filed subsequent to the effectiveness of this registration statement pursuant to Section 305(b)(2) of the Trust Indenture
Act of 1939, as amended.
†
Previously filed.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New York, New York, on June 21, 2021.
|
|
PROTAGENIC
THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Garo H. Armen
|
|
|
Name:
|
Garo
H. Armen
|
|
|
Title:
|
Chairman
(Principal Executive Officer and Duly Authorized Officer)
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/
Garo H. Armen
|
|
Director
and Chairman of the Board
|
|
June
21, 2021
|
|
Garo
H. Armen
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/
Alexander K. Arrow
|
|
Chief
Financial Officer
|
|
June
21, 2021
|
|
Alexander
K. Arrow
|
|
(Principal
Financial Officer)
|
|
|
|
|
|
|
|
|
|
/s/
Robert B. Stein*
|
|
Director
and Chief Medical Officer
|
|
June
21, 2021
|
|
Robert
B. Stein
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Khalil Barrage*
|
|
Director
|
|
June
21, 2021
|
|
Khalil
Barrage
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Brian Corvese*
|
|
Director
|
|
June
21, 2021
|
|
Brian
Corvese
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Jennifer Buell*
|
|
Director
|
|
June
21, 2021
|
|
Jennifer
Buell
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Joshua Silverman*
|
|
Director
|
|
June
21, 2021
|
|
Joshua
Silverman
|
|
|
|
|
|
*
By:
|
/s/
Alexander K. Arrow
|
|
|
|
Alexander
K. Arrow
|
|
|
|
Attorney-in-fact
|
|
Exhibit
Index
|
1.1*
|
|
Form
of Underwriting Agreement.
|
|
3.1†
|
|
Third
Amended and Restated Certificate of Incorporation of Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s
Current Report on Form 8-K, as filed with the SEC on June 20, 2016).
|
|
3.2†
|
|
Certificate
of Designations, Powers, Preferences and Other Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof
of Series B Convertible Preferred Stock of Atrinsic, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report
on Form 8-K, as filed with the SEC on February 5, 2016).
|
|
3.3†
|
|
Second Amended and Restated Bylaws Protagenic Therapeutics, Inc., (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 1, 2018).
|
|
4.1*
|
|
Form
of warrant agreement and warrant certificate
|
|
4.2*
|
|
Form
of specimen preferred stock certificate
|
|
4.3*
|
|
Certificate
of designation for preferred stock
|
|
4.4†
|
|
Form of Indenture with respect to senior debt securities, between the registrant and one or more trustees to be named.
|
|
4.5†
|
|
Form of Indenture with respect to subordinated debt securities, between the registrant and one or more trustees to be named.
|
|
4.6*
|
|
Form
of debt security
|
|
4.7*
|
|
Form
of rights agreement
|
|
5.1†
|
|
Opinion of Duane Morris LLP.
|
|
21.1†
|
|
Subsidiaries
(Incorporated by reference to Exhibit 21.1 to Company’s Annual Report on Form 10-K, as filed with the SEC on
March 24, 2021)
|
|
23.1†
|
|
Consent of MaloneBailey, LLP, Independent Registered Public Accounting Firm.
|
|
23.2†
|
|
Consent of Duane Morris LLP (included in Exhibit 5.1).
|
|
24.1†
|
|
Powers of Attorney
|
|
25.1**
|
|
Statement
of Eligibility of Trustee on Form T-1 of Trustee under the Senior Debt Indenture.
|
|
25.2
**
|
|
Statement
of Eligibility of Trustee on Form T-1 of Trustee under the Subordinated Debt Indenture.
|
*
To the extent applicable, to be filed by a post-effective amendment or as an exhibit to a document filed under the Exchange Act
and incorporated by reference herein.
**
To be filed subsequent to the effectiveness of this registration statement pursuant to Section 305(b)(2) of the Trust Indenture
Act of 1939, as amended.
†
Previously filed.
Protagenic Therapeutics (NASDAQ:PTIX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Protagenic Therapeutics (NASDAQ:PTIX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
